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The correlation between myopia and intraocular inflammation has rarely been 
explored. The aim of this article is to review myopic changes induced by inflammatory 
diseases and inflammatory diseases related to myopia, followed by a discussion on 
inflammatory choroidal neovascularization. Clinical cases are used to illustrate these 
conditions. The review does not include inflammatory conditions caused by surgical 
interventions employed for treatment of myopia. Uveitic conditions that can induce 
a myopic shift include sclero-choroidal inflammation, lens induced myopia due to 
steroid cataracts, juvenile idiopathic arthritis (JIA) induced myopia, and transient 
drug induced myopia due to sulfonamides and acetazolamide used for treatment of 
ocular toxoplasmosis and inflammatory cystoid macular edema, respectively. Most 
inflammatory conditions related to myopia are conditions involving the choriocapillaris. 
These include multifocal choroiditis and/or punctate inner choroiditis, multiple 
evanescent white dot syndrome and acute idiopathic blind spot enlargement. It 
can be hypothesized that fragility of the choriocapillaris due to particular anatomic 
changes due to myopia, together with unknown immunogenetic factors predispose 
myopic eyes to primary inflammatory choriocapillaropathies.
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INTRODUCTION
The correlation between myopia and inflamma-
tion can be subdivided into three major 
situations. The first category is particular 
consequences of inflammation which develop 
in highly myopic eyes; the second is myopia 
related to intraocular inflammation due to 
changes in the lens-iris diaphragm or as a side 
effect of therapy, including cataracts induced 
by corticosteroid therapy and drug induced 
myopic shift; the third category consists of 
conditions in which myopia is linked to the 
development of certain inflammatory eye 
diseases including multifocal choroiditis and its 
sub-entity, punctate inner choroiditis, as well 
as multiple evanescent white dot syndrome 
and acute idiopathic blind spot enlargement. 
Inflammatory eye diseases related to myopia 
have a high propensity to cause inflammatory 
choroidal neovascularisation (CNV), a condition 
that will be further discussed thereafter.Myopia and Inflammation; Herbort et al
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CONSEQUENCES OF INFLAMMATION IN 
HIGH MYOPIA
Extreme caution should be exercised with 
corticosteroid therapy for uveitis in highly myopic 
eyes. It is well known that high myopia predisposes 
to glaucoma and visual field loss.1,2,3 These 
eyes are more susceptible to pressure increase 
following the administration of corticosteroids, 
the so-called steroid response.4 In addition to 
pressure increase, further myopization can occur 
due to decreased resistance of the thinned sclera 
in highly myopic eyes. These facts mandate close 
follow-up for highly myopic patients receiving 
corticosteroids in any form for treatment of 
uveitis. Routes of administration which can be 
terminated promptly, such topical or systemic 
corticosteroids, are preferred to periocular or 
subtenon injections of depot steroids.
MYOPIC SHIFT INDUCED BY UVEITIS
Uveitis can cause acute, transient or constitutive 
myopization in different contexts. These include 
acute inflammation such as in choroidal or 
scleral inflammation, chronic uveitis as in 
juvenile idiopathic arthritis (JIA) related 
uveitis, as a consequence of therapy such 
as lens related myopization following long-
term corticosteroid therapy and the use of 
sulfonamides for treatment of toxoplasmic 
retinochoroiditis or acetazolamide for cystoid 
macular edema (CME).
Acute myopia due to sclero-choroidal 
inflammation
Severe inflammation in posterior scleritis can 
cause acute myopization in some cases.5 The 
possible mechanism is supraciliary exudation 
causing relaxation of zonular fibers and 
increased convexity of the crystalline lens. 
This phenomenon is also noted with severe 
choroidal inflammation such as in hyperacute 
Vogt-Koyanagi-Harada (VKH) disease that 
frequently causes acute myopia due to ciliary 
body detachment and inflammatory supraciliary 
exudation which can be detected by ultrasound 
biomicroscopy (UBM).6,7
Illustrative case of VKH disease
A twenty-year-old female patient consulted 
her ophthalmologist for bilateral blurred vision 
since several days ago. She reported flu-like 
symptoms and headache in the previous week. 
Examination showed bilateral myopic shift to 
–1.75 despite the fact that the patient had always 
been emmetropic. Best corrected visual acuity 
(BCVA) was 20/20 in both eyes with appropriate 
correction. Anterior segment examination 
revealed faint anterior chamber (AC) flare 
and rare cells in both eyes. Rare occasional 
cells were also noted in both vitreous cavities. 
Fundus examination disclosed wrinkling of the 
vitreoretinal interface as well as disc hyperemia 
in both eyes. The treating ophthalmologist was 
advised to perform dual fluorescein (FA) and 
indocyanine green angiography (ICGA). FA 
showed early non-homogeneous filling of the 
choriocapillaris with areas of delayed filling 
in both eyes. (Fig. 1A) On late frames, disc 
hyperfluorescence was noted as well as some 
areas of faint mottled retinal hyperfluorescence 
(Fig. 1B). ICGA demonstrated inflammation 
of choroidal vessels (Fig. 1C) as well as small 
regularly sized hypofluorescent dark dots 
evenly distributed in the posterior pole and 
mid-periphery (Fig. 1D). A diagnosis of VKH 
disease was posed and we suggested that the 
patient be referred for immediate treatment 
with intravenous corticosteroids. Unfortunately, 
Figure 1A. Hyperacute VKH, nonhomogeneous filling 
of the choriocapillaris.
Figure 1B. Hyperacute VKH, patchy hyperfluorescence 
on FA.Myopia and Inflammation; Herbort et al
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the patient was sent home over the weekend 
to be seen again three days later for further 
investigations. At this time, she became 
hypermetropic by 2.0 diopters in both eyes. 
Repeat FA showed vast areas of subretinal 
pooling. On ICGA, exudative retinal detachments 
were seen as hypofluorescent geographic areas 
while regular small hypofluorescent dark 
dots were still present (Fig. 1E). UBM showed 
supraciliary exudation (Fig. 1F) explaining the 
myopization that had occurred before exudative 
retinal detachments reversed the condition to 
hypermetropia.
Lens induced myopia due to steroid cataracts
A longitudinal study has shown that after 
corticosteroid therapy in uveitis, development 
of corticosteroid lens changes is accompanied 
by a marked increase in lens induced myopia 
up to more than 7 diopters due to the optical 
effect of the posterior subcapsular cataract.8
Myopia induced by JIA-related uveitis
The relationship between refractive errors and 
JIA uveitis was analyzed in 65 adult patients.9 
Refractive data were obtained at an average 
of 26.4 years after the onset of JIA uveitis, 
a disease developing in early childhood. 
Significantly more myopic refractive errors 
were found in JIA patients when compared to 
an age-matched control group. About 43% of 
patients had increased negative refractive error 
suggesting an association between myopia and 
JIA. A possible explanation for these findings 
Figure 1C.  Hyperacute VKH disease, early 
hyperfluorescence of choroidal vessels and leakage from 
choroidal stromal vessels indicating choroidal vasculitis.
Figure 1D.  Hyperacute VKH disease, note numerous 
regularly sized and evenly distributed hypofluorescent 
dark dots on a background of diffuse choroidal 
hyperfluorescence, indicating granulomas of the choroid.
Figure 1E. Hyperacute VKH disease, exudative retinal 
detachments shown on ICGA in the left eye. Note the 
numerous dark dots indicating choroidal granulomas.
Figure 1F. Hyperacute VKH disease, UBM image shows 
supraciliary effusion explaining myopization.Myopia and Inflammation; Herbort et al
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is weakening of scleral connective tissue 
due to chronic inflammation predisposing to 
myopization.
Transient drug-induced myopia
Several treatment regimens used in toxoplasmic 
retinochoroiditis contain agents from the 
sulfonamide family which may cause transient 
myopia.10 UBM explains this mechanism by 
demonstrating supraciliary choroidal effusion 
causing forward displacement of the ciliary 
body-lens-iris block and relaxation of zonular 
fibers leading to myopia, anterior chamber 
shallowing and angle closure glaucoma.11 
The same mechanism can also occur when 
acetazolamide is used to treat inflammatory 
CME, since this agent also belongs to the 
sulfonamide family.12,13 Discontinuation of 
these medications leads to complete resolution 
of this anatomic shift. Recently, several reports 
of a similar condition have been published 
following the use of topiramate, a sulfonamide 
derivative used for treatment of migraine 
headaches, seizures, alcohol abuse and other 
drug dependencies.14
INFLAMMATORY EYE DISEASE LINKED 
WITH MYOPIA
Multifocal choroiditis
Multifocal choroiditis (MFC) is a recurrent 
bilateral chorioretinal inflammatory disease. 
Some authors further subdivide this entity into 
punctuate inner choroidopathy (PIC), a subset 
of MFC which usually occurs in young myopic 
patients, often involving the more myopic 
eye. The entity known as presumed ocular 
histoplasmosis syndrome (POHS) should also 
be included under the same group since its 
clinical and ICGA features are indistinguishable 
from MFC and both conditions probably 
represent the same clinical entity. Separation 
of these conditions is probably not warranted 
since their pathophysiology is the same, i.e. 
choriocapillaris perfusion irregularities or 
nonperfusion.15 MFC was clearly associated 
with myopia with an average refractive error 
of -2.19 diopters in a study analyzing the whole 
group of inflammatory choriocapillaropathies 
(formerly white dot syndromes).16
Symptoms, as in other inflammatory 
choriocapillaropathies, usually include 
photopsia, scotomata and loss of visual acuity as 
well as visual field defects. Fundus examination 
reveals small faintly visible active foci and 
older clearly visible yellow chorioretinal scars. 
Vitreous cells can be seen in the posterior 
vitreous during active disease.
The most useful complementary 
investigation is ICGA which shows two types 
of lesions, one are hypofluorescent dots seen in 
early, intermediate and late angiographic phases 
indicating chorioretinal scars that correspond 
to late hyperfluorescent non- diffusing areas 
on FA. During active disease, ICGA shows 
additional hypofluorescent areas, not apparent 
or barely visible as faint late hyperfluorescent 
areas on FA, indicating choriocapillaris non-
perfusion.17-19 These ICGA lesions are reversible 
and usually respond to systemic or subtenon 
corticosteroids or triamcinolone injections.
Additional investigations should include 
visual field testing as in all other inflammatory 
choriocapillaropathies, which will show 
scotomata in areas with active disease and an 
enlarged blind spot; findings that are more 
pronounced than fundus lesions. It is important 
to exclude other causes of uveitis, especially 
infectious conditions such as tuberculosis.
A special feature of multifocal choroiditis 
is the propensity of the disease to become 
complicated by subretinal inflammatory CNV 
which is present in up to 30%-40% of cases, 
a proportion much higher than any other 
inflammatory choriocapillaropathy.
Management, as for other entities under 
this group, is empirical. Although there are 
no controlled studies, clinical experience is 
probably sufficient to recommend corticosteroid 
therapy in cases with active disease; this can 
usually be diagnosed when patients complain 
of photopsia and is further evidenced by 
ICGA. If corticosteroids are insufficient, 
immunosuppressive agents may be added. 
The best follow-up parameter is ICGA which 
can show resolution of hypofluorescent areas. Myopia and Inflammation; Herbort et al
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If inflammatory subretinal CNV is present, 
corticosteroids (subtenon injections or systemic) 
should be tried first with concomitant or 
subsequent intravitreal anti-vascular endothelial 
growth factor (VEGF) therapy.
The outcome of MFC is often favorable if 
recurrences are detected early (using ICGA) and 
treated appropriately. The course is deleterious 
if follow-up is inadequate or if central lesions 
occur.
Illustrative case of MFC
A 30-year-old myopic female patient who had 
experienced several episodes of ocular symptoms 
including photopsia and scotomata since the 
age of 25 consulted her ophthalmologist. 
Retrospectively, these were considered to be 
the first episodes of MFC. At presentation, 
she complained of photopsia and subjective 
scotomata in her left eye. Refractive error was 
–10.50–1.75@26º and –9.50–1.25@158º in the right 
and left eyes, and BCVA was 20/25 and 20/20 
respectively. There was no anterior segment 
inflammation and laser flare photometry values 
were within normal limits. There were rare 
vitreous cells in the left eye. Fundus examination 
revealed multiple foci that seemed atrophic 
and accounted for previous episodes of MFC 
(Fig. 2A). On ICGA, dark dots corresponding 
to chorioretinal scars were seen in the right 
eye. In the left eye, in addition to the same 
dark dots, there was a widespread geographic 
area of hypofluorescence indicating extensive 
choriocapillaris non-perfusion (Fig. 2B) which 
was not detectable on FA (Fig. 2C).
A course of systemic prednisolone was 
started at 50 mg per day and tapered over 
a period of 4 months. This treatment course 
was probably too short since several months 
later, a CNV developed in the right macula 
Figure 2A. Fundus appearance in multifocal choroiditis 
(MFC). Right and left fundus frames of a case of MFC 
showing typical dispersed lesions. No sign of disease 
recurrence appears in the left eye.
Figure 2B.  ICGA in multifocal choroiditis. ICGA 
shows widespread non-perfusion in the left eye not 
apparent on fundus photographs (Fig. 2A) nor on FA 
(Fig. 2C). Only ICGA allows detection of recurrence, an 
example of ICGA “iceberg” and “submarine” concepts 
indicating that ICGA signs can be pronounced despite 
minimal or absent fundus or FA signs. Note also the 
extensive ischemia which explains the high percentage 
of choroidal neovascularization in MFC. Right eye is 
currently inactive. (Courtesy of Alessandro Mantovani, 
Como, Italy).
Figure 2C.  FA in multifocal choroiditis. As shown in 
figure 2B, extensive ICGA signs can be present in the 
absence of fundus or FA signs.Myopia and Inflammation; Herbort et al
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concomitant with recurrence of MFC in the 
same eye, very well evident on ICGA which 
revealed choriocapillaris non-perfusion; dark 
dots representing old cicatricial foci were also 
present (Fig. 2D). Corticosteroid therapy was 
resumed at this stage; as anti-VEGF agents 
were not available at the time, three courses 
of photodynamic therapy were performed 
leading to cicatrization of the CNV (Fig. 2E). 
Nowadays, more aggressive and prolonged 
immunosuppressive therapy is employed in 
such cases.
Punctate inner choroidopathy
Punctate inner choroidopathy (PIC) is a subset of 
MFC characterized by a similar clinical picture as 
far as symptoms, fundus signs and neovascular 
complications are concerned, except that the 
lesions are smaller. In the original description 
by Watzke and colleagues, the disease was 
reported to be bilateral and predominant in 
myopic women.17
In an extensive report on MFC and PIC, the 
latter was found to be bilateral in more than 
80% of cases.20 In the experience of some of us, 
the disease tends to be unilateral predominantly 
involving the more myopic of fellow eyes.15 Like 
multifocal choroiditis, in our hands, new lesions 
respond to systemic or subtenon corticosteroids 
and additional immunosuppressive therapy 
is not always necessary. Corticosteroids are 
also thought to have a beneficial effect on the 
neovascular membrane and are the first line 
of treatment.
Illustrative case of PIC
A 26-year-old female patient presented with 
photopsia in her left eye. Refractive error was 
–10.50–1.0@22º and –11.50–1.50@142º in the 
right and left eyes respectively with BCVA of 
20/20 in both eyes. The anterior segment had 
no signs of inflammation but there were scarce 
vitreous cells in the left eye. Fundus examination 
was within normal limits in the right eye but 
on the left side, there were a few cicatricial 
foci in the posterior pole (Fig. 3A). Octopus 
visual field (VF) was normal in the right eye 
but showed several confluent central scotomata 
in the left eye (Fig. 3B). FA was within normal 
limits on the right side but showed several late 
hyperfluorescent spots indicating window-
defects, ICGA showed patchy hypofluorescence 
extending beyond the hyperfluorescent areas 
seen on FA (Fig. 3C, top images). A diagnosis 
of multifocal choroiditis (PIC type) in the 
left eye was made. Systemic corticosteroid 
treatment was initiated starting at dose of 60 
mg per day, tapered over a period of 6 months. 
After one month of treatment, FA remained 
unchanged, but ICGA revealed a decrease in 
Figure 2D.  Choroidal neovascularization complicating 
MFC shown on ICGA (left) and FA (right). As shown in 
figure 2B, choriocapillaris ischemia is usually extensive 
in MFC and can only be detected by ICGA. This 
figure shows the development of CNV in the right eye 
(crimson arrow) concomitant with an acute recurrence 
of MFC causing extensive choriocapillaris ischemia 
(black arrows) not visible on FA. The darker areas are 
old cicatricial foci that can also be seen on FA (window 
defects, yellow arrows). (Courtesy of Alessandro 
Mantovani, Como, Italy)
Figure 2E. Cicatricial CNV treated by photodynamic 
therapy in MFC. The old cicatricial lesions that were 
seen on ICGA (very dark spots) and FA (window defect 
hyperfluorescence) are well identified.Myopia and Inflammation; Herbort et al
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hypo-fluorescent areas (Fig. 3C, middle images) 
parallel with an improvement in VF (Fig. 3B). 
After 4 months of corticosteroid therapy, all 
new lesions seen on ICGA regressed leaving 
behind only dark areas corresponding to old 
cicatricial atrophic areas seen on FA (Fig. 3C, 
bottom images). At 6 months, corticosteroids 
were discontinued and no recurrence was noted 
over 11 years of follow-up. It is noteworthy 
that PIC developed in the more myopic eye. 
Without ICGA, the recurrence would not have 
been detected and healing under corticosteroids 
could only be monitored by ICGA. On FA, no 
more cicatricial lesions appeared indicating 
that the new lesions responded well to therapy 
and did not lead to additional scars. The term 
“ICGA submarine effect” may be used under 
circumstances as in this case, when lesions 
detectable by ICGA are absolutely not visible 
on FA and/or fundus examination.
Multiple evanescent white dot syndrome
Multiple evanescent white dot syndrome 
(MEWDS) is characterized by faint yellowish-
Figure 3B. Octopus visual field at presentation and 
during follow-up. Extensive centrally coalescent 
scotomata at presentation (left). Significant improvement 
after one month of corticosteroid therapy (middle) and 
complete recovery after six months of treatment (right). 
(Source of illustration: reference 18)
Figure 3C. Evolution of FA (left column) and 
ICGA lesions (right column) at presentation and 
under corticosteroid treatment for punctate inner 
choroidopathy. At presentation (top images), FA only 
shows cicatricial lesions from old foci (window defects) 
and does not reveal the extensive occult recurrence 
shown by ICGA. After one month of systemic therapy, 
FA frames show the same cicatricial lesions (middle 
left) whereas the fresh lesions have regressed on ICGA 
(middle right). After 6 months of corticosteroid therapy 
(bottom images), FA shows the same appearance of 
old cicatricial lesions whereas ICGA shows complete 
regression of the fresh lesions; old atrophic scars due to 
episodes are also visible on FA frames.
Figure 3A.  Punctate inner choroiditis, fundus image 
of the left eye shows one larger chorioretinal scar and 
several faint choroiditis foci. New recurrent lesions are 
not detectable.Myopia and Inflammation; Herbort et al
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white fundus lesions, slight papillary 
swelling, and moderate to severe drop in 
visual acuity as well as visual field defects. It 
is usually unilateral, limited to one episode 
and predominant in middle aged women but 
can be seen at any age.21 MEWDS is clearly 
associated with myopia as shown in at least 
two studies.16,22 Disease characteristics have 
been thoroughly described in the first two 
articles reporting this condition.23,24 The authors 
localized the functional impairment to the level 
of the outer retina but failed to identify the 
mechanism of disease. Today, it is clear that 
MEWDS definitively belongs to the group of 
primary inflammatory choriocapillaropathies 
(PICCPs).25,26
Symptoms include a viral flu-like prodrome, 
often two weeks preceding ocular symptoms, 
in up to 50-60% of cases; other symptoms 
typically include photopsia and scotomata. 
There is moderate to severe drop in visual 
acuity and visual field defects in over 90% of 
cases. Fundus findings include discrete yellow-
white discolorations up to the mid-periphery 
in acute disease, and a granular appearance 
in the macula during the subacute phase. In 
some cases, an enlarged blind spot is detected 
and this subgroup is termed acute idiopathic 
blind spot enlargement (AIBSE) because other 
findings typical of MEWDS are not present.
The most useful diagnostic procedure is 
ICGA which shows hypofluorescent dots and 
peripapillary hypofluorescence in the acute 
phase which resolve over 4-8 weeks. FA shows 
discrete hyperfluorescent foci present on early 
frames or moderate disc hyperfluorescence; 
however FA may reveal no significant. 
Additional investigations may include full-
field ERG which is abnormal in up to 80% 
of cases indicating widespread ischemia in 
the outer retina. The course of the disease is 
characterized by spontaneous resolution of signs 
and symptoms 6-10 weeks in nearly all cases.
Illustrative case of MEWDS
A 33-year-old female patient consulted her 
ophthalmologist 2 weeks after sensing floaters 
in her left eye. She also complained of a veil 
in front of her left eye and reported photopsia 
in same eye. The major symptom however, 
was the sensation of dark spots that tended 
to increase. Refractive error was –1.25–0.50@8º 
and –0.75–0.50@180º in the right and left eyes 
with BCVA of 20/20 in both eyes. Both anterior 
segments were non-inflamed and flare measured 
by laser photometry was within normal limits 
in both eyes. No inflammatory cells were 
present in the vitreous of both eyes. A slightly 
nonhomogeneous texture was noted in the left 
macula (Fig. 4A). Optical coherence tomography 
was within normal limits in both eyes.
Octopus visual field was normal in the 
right eye but showed several relative scotomata 
in the left one with a slight increase in mean 
defect (2.6 dB versus 0.1 dB in the unaffected 
right eye) (Fig. 4B). FA showed faint and tiny 
areas of hyperfluorescence and a leaking disc 
on late FA frames. On ICGA, geographic zones 
of hypofluorescence in the posterior pole were 
clearly identified, more clearly so in the late 
frames (Fig. 4C). This is a typical situation 
illustrating the “iceberg effect” on ICGA which 
is characterized by relative absence of signs 
on fundus examination and FA despite clear 
and widespread ICGA lesions. Fundus auto-
fluorescence (FAF) was increased corresponding 
to hypofluorescent areas seen on ICGA; this 
regressed in the convalescent phase (Fig. 4D). 
Symptoms and visual field recovered within 
7 weeks (Fig. 4B).
Figure 4A. Fundus image of the left eye in a patient 
with MEWDS. The fundus is almost normal with only a 
slightly nonhomogeneous appearance in the fovea.Myopia and Inflammation; Herbort et al
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Acute idiopathic blind spot enlargement
Acute idiopathic blind spot enlargement 
(AIBSE) was first described in 1988 in a report 
including 7 patients who presented with 
peripapillary scotomata leading to symptomatic 
enlargement of the blind spot confirmed by 
visual field testing. All patients were young, 
25 to 39 years of age, with 5/2 female/male 
predominance.27 Visual acuity, color vision, 
pupillary responses, funduscopy and FA 
were all normal. The only abnormal finding 
was an abnormal focal ERG indicating retinal 
dysfunction around the optic disc at the origin 
of the visual field defect. Most probably, AIBSE 
and MEWDS are the same disease entity; the 
only difference is that fundus abnormalities in 
MEWDS are not present in AIBSE. As indicated 
by Hamed et al, the retinal lesions may already 
have subsided at the time of examination or 
may have been subclinical.28 If ICGA had been 
available and performed by the authors of this 
and subsequent reports, it is probable that 
AIBSE would never have been described as a 
separate clinical entity. ICGA is currently the 
method of choice for making a diagnosis of 
atypical MEWDS cases in patients presenting 
at later stages or with subclinical disease.16 
Numerous reports on blind spot enlargement 
in many of the diseases presently reclassified 
under PICCPs indicate the presence of common 
physiopathogenic mechanisms.29,30 Furthermore, 
reports including ICGA show that visual 
field alterations are related to peripapillary 
hypofluorescence indicating choriocapillaris 
non-perfusion as the physiopathogenic 
process causing blind spot enlargement. This 
pathologic characteristic, found in many of 
the PICCPs, may indicate susceptibility of 
the peripapillary choriocapillaris to occlusion 
following inflammation leading to outer 
Figure 4C. FA and ICGA frames in a patient with 
MEWDS. FA (top images) shows tiny hyperfluorescent 
spots in the posterior pole and disc leakage on the 
late frame (top right). ICGA (bottom images) shows 
extensive areas of choriocapillaris non- perfusion in the 
posterior pole, well visible in the intermediate phase 
(bottom left) but much clearly outlined in the late phase 
(bottom right).
Figure 4D. Fundus auto-fluorescence (FAF) in MEWDS. 
Geographic and confluent areas of increased FAF in the 
left diseased eye (middle picture) corresponding to dark 
ICGA areas which almost completely recovered in the 
healing stage (right image).
Figure 4B. Octopus visual fields in MEWDS. Slight 
increase in mean defect (MD) and shallow relative 
scotoma at presentation (top image) with normalization 
7 weeks later during the healing phase.Myopia and Inflammation; Herbort et al
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retinal ischemia and dysfunction, producing 
a peripapillary scotoma.
INFLAMMATORY CHOROIDAL 
NEOVASCULARIZATION
The role of inflammatory factors in CNV
A comprehensive work on inflammatory 
neovascularization has recently been published 
by P. Neri and the concepts presented herein are 
largely based on this work.31 Neoangiogenesis 
can occur in the presence or absence of 
evident inflammatory activity or can occur 
as a late complication of chronic low-grade 
inflammation. Inflammation can be subtle and 
choroidal lesions can often be undetectable. 
Choroidal inflammation is often missed unless 
ICGA is employed which should be considered 
mandatory for this group of disorders.18 This 
concept has been proven in animal models, 
including posterior experimental uveitis which 
features CNV as a late sequel.32-34 Surgically 
removed inflammatory CNVs have shown, 
on histological examination, the presence of 
inflammatory cells such as macrophages and 
lymphocytes in a higher proportion as compared 
to specimens obtained from eyes with age 
related macular degeneration (ARMD).35
Unfortunately, there is lack of histological 
studies on inflammatory CNV in humans as 
surgical removal is becoming less frequent 
with the development of efficient non-surgical 
treatments for CNV. The use of animal models 
has provided some information on the role 
of cells and biological mediators in the 
pathogenesis of CNV. Macrophage recruitment 
to the choroid seems to be central in the 
pathogenesis of CNV: Espinosa-Heidmann et 
al36 conducted a study to determine whether 
treatment with clodronate liposomes (CL2MDP-
lip), which causes depletion of blood monocytes 
and lymph node macrophages, diminishes 
the severity of neovascularisation in a mouse 
model of laser-induced CNV. Recently, Jost 
et al37 proved the crucial role of plasminogen 
activator inhibitor-1 (PAI-1) in neoangiogenesis; 
the authors stated that balance between serine 
proteases and PAI-1 was critical for pathological 
angiogenesis. The large number of pathways 
involved in the pathogenesis of CNV and the 
peculiarity of the immune system within the 
eye make this process difficult to understand.
The crucial role of ICGA in inflammatory 
CNV: the “iceberg” and “submarine” effects
Both MFC/PIC and MEWDS are classified 
under PICCPs, formerly called the “white 
dot syndromes”. Their diagnosis relies on 
certain ICG angiographic signs seen in this 
category of diseases.18,19,38 In inflammatory 
choriocapillaropathies, ICGA signs in the 
acute phase of the disease include irregular 
patchy or geographical hypofluorescent areas 
of variable size present in early, intermediate 
and late frames. (Figures 2B, 3C and 4C) This 
sign indicates choriocapillaris non-perfusion 
or hypoperfusion and is usually more clearly 
visible on late frames (after 28-35 seconds) after 
partial washout of ICG from the choroid. Very 
often, peripapillary ICG hypofluorescence is 
identified. In the convalescent phase, most of 
these hypofluorescent lesions regress. If ICGA 
hypofluorescent areas persist in the post-acute 
phase, they represent choroidal atrophy and 
scarring, changes that never occur in MEWDS.
FA is less consistent and less helpful in 
choriocapillaritis. Early phase FA frames, in 
the acute stage of the disease and parallel 
with ICGA, show early hypofluorescent areas 
indicating choriocapillaris non perfusion but 
only complementary ICGA can differentiate 
between perfusion delay or actual non-
perfusion, as FA gives no more information 
on the choriocapillaris later than 60-70 seconds 
after fluorescein infusion.
In MEWDS, faint hyperfluorescence can 
be seen fairly early. Late fluorescein frames 
in the acute phase of the disease show 
hyperfluorescent areas going from faint to 
profuse hyperfluorescence depending on the 
severity of ischemia in the outer retina. In 
MEWDS, as in MFC, FA findings can be very 
faint (Fig. 4C) or even absent. We speak of 
the “iceberg effect” when ICGA findings are 
out of proportion to what fundus examination 
and/or FA reveal. The term “submarine effect” Myopia and Inflammation; Herbort et al
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is used when ICGA choroidal lesions are 
completely non-detectable by both funduscopy 
and fluorescein angiography.
Ischemic factors in inflammatory CNV
In PICCPs, there are double stimuli which 
promote the development of CNV. In addition 
to inflammatory factors that can trigger CNV 
alone such as in VKH, ischemia is always 
present in choriocapillaritis and adds to the 
inflammatory stimulus. Since each stimulus 
by itself can trigger CNV, this is a situation 
in which there is maximal danger for CNV 
formation. In choriocapillaris closure, ischemia 
is present at the level of the RPE but also more 
importantly in the outer retina which explains 
visual field dysfunction. When ischemia is 
very severe, it provokes “rescue” dilatation 
of inner retinal vessels accounting for late 
fluorescein staining and pooling that can be 
seen in severe cases of MFC and is classically 
seen in acute multifocal ischemic choroiditis 
(AMIC), also called APMPPE (acute posterior 
multifocal placoid pigment epitheliopathy) 
which is a misnomer since the primary process 
is not at the level of the pigment epithelium. 
In some PICCPs such as MFC, choriocapillaris 
non-perfusion is very frequent and extensive, 
when searched for by ICGA, explaining the 
high rate of CNV. In other entities such as 
MEWDS, ischemia is less important and less 
widespread decreasing, but not eliminating 
the risk of CNV. Very discrete choriocapillaris 
involvement, not detectable by any means other 
than ICG, can nevertheless trigger CNV39,40 
and these cases probably account for the non-
entity of idiopathic CNV because ICGA is still 
not routinely performed in these situations in 
a great number of ICGA refractory countries.
Treatment of inflammatory CNV
The treatment of inflammatory CNV is still a 
challenge, since no guidelines are available. 
Treatment modalities have not been tested in 
controlled trials and are only based on case 
reports or case series at best.
Laser photocoagulation41, periocular 
and systemic steroids42, PDT43,44, immune 
suppression45 and surgical removal46 have been 
employed for management of inflammatory 
CNV in the pre anti-VEGF era.47
The inflammatory process leading to 
inflammatory CNV is not only regional, in 
fact the whole immune system seems to be 
involved.48 For such reasons, systemic steroids 
should always be considered as the primary 
approach to treat choroidal neovascular 
membranes.
The safety and efficacy of immune 
suppression45 for control of CNV in uveitis has 
been described. Cyclosporine A49 and other 
calcineurin inhibitors can also be used for 
treatment; mycophenolate mofetil (MMF) may 
offer a more favorable safety and efficacy profile 
and is a promising drug for long-term control 
of inflammatory CNV as recently described.50
As soon as PDT was introduced, argon 
laser photocoagulation was limited to treatment 
of extrafoveal neovascular membranes in 
order to reduce the risk of iatrogenic damage. 
Different strategies have been proposed for 
PDT; some cases have been treated electively 
with corticosteroid/immunosuppressive 
therapy and PDT43, or PDT was used only in 
case other approaches such as inflammation 
suppressive therapies had failed.44 A this time, 
anti-VEGF agents play a prominent role in the 
management of inflammatory CNV51,52 and have 
marginalized the role of PDT as well as that 
of surgery; CNV surgical removal is indicated 
only for extensive peripapillary membranes.53
Although different treatments have not 
been compared “head to head”, the standard 
of care nowadays consists of corticosteroid/
immunosuppressive treatment as the first choice 
for juxta/sub-foveal CNV, almost invariably 
administered in combination with intravitreal 
anti-VEGF agents.
CONCLUSIONS
To the best of our knowledge, the relationship 
between myopia and inflammatory ocular 
diseases and its reverse, myopization in relation 
to inflammation, have not been studied in the 
last 30 years. In 1976, a report entitled “myopia Myopia and Inflammation; Herbort et al
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and uveitis” was published in a Romanian 
journal.54 It is noteworthy to realize that acute 
inflammation of the sclera such as scleritis and 
diseases of the choroid such as VKH disease 
can induce myopization when the disease is 
hyperacute. Sulfonamides used in the treatment 
of toxoplasmosis and sulfonamide derived 
drugs such as acetazolamide employed in 
inflammatory CME may rarely lead to forward 
shift of the ciliary body-lens-iris diaphragm, and 
cause myopization and angle closure glaucoma. 
On the other hand, myopia predisposes to 
several ocular inflammatory conditions such 
as MFC and MEWDS. It should be noted that 
both of these entities are PICCPs. It may be 
hypothesized that structural globe changes 
due to myopia cause choriocapillaris/retinal 
pigmentary epithelium complex fragility, 
rendering it prone to inflammatory diseases.
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